Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
SPIRIT-Children
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting of paediatric randomised controlled trial protocols involving participants aged 0-19 years. |
| Full bibliographic reference | Baba A, Smith M, Potter BK, Chan AW, Moher D, Toulany A, Doherty-Kirby A, Nafria Escalera B, Stratton C, Gale C, Macarthur C, Purper-Ouakil D, Juszczak E, Cohen E, Reggiardo G, Preston J, Cohen JF, Upton J, Allegaert K, Boerner K, Mehta K, Nguyen KA, Courtney K, Hartling L, Konstantinidis M, Odermarsky M, Butcher NJ, Kolehmainen N, Longmuir PE, Gill PJ, Leroy P, Feneberg R, Poluru R, Morris SK, Friedrichsdorf SJ, Chute Nagy T, Klassen TP, Lacaze-Masmonteil T, Onland W, Offringa M. SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocols. This guideline was published simultaneously in 3 journals. You can read the guideline in any of these journals using the links below. BMJ 2026; 392: e085062. PMID: 41734969 JAMA Pediatrics 2026; 180: 426-439. PMID: 41734892 Lancet Child and Adolescent Health 2026; 10: 284-296. |
| Language | English |
| DOI | 10.1136/bmj-2025-085062 |
| PubMed ID | 41734969 |
| Relevant URLs (full-text if available) |
Fillable checklists (PDF) and tip sheets for both extensions are available on https://lab.research.sickkids.ca/enrich/reporting-standards/spirit-consort-c/ |
| Explanation and elaboration papers | |
| Relevant more generic / specialised reporting guidelines (i.e. main generic guideline or extension to a generic guideline) |
Specialised SPIRIT-PRO: Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT; and the SPIRIT-PRO Group. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-494. Link to abstract SPIRIT-TCM: Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, Chan AW, Shang HC, Bian ZX. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-79. PMID: 30484022 SPENT 2019: Porcino AJ, Shamseer L, Chan A-W, Kravitz RL, Orkin A, Punja S, Ravaud P, Schmid CH, Vohra S; on behalf of the SPENT group. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368. Link to full-text. SPIRIT-AI: Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ; on behalf of the SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension. BMJ. 2020;370:m3210. PMID: 32907797 Nat Med. 2020;26(9):1351–1363. PMID: 32908284 Lancet Digital Health. 2020;2(10):e549-e560. PMID: 33328049 SPIRIT-Path: Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, Lewis I, Chan AW, Harrison DJ; SPIRIT-Path group. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e445. PMID: 34592193 SPIRIT-Outcomes: Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-2356. PMID: 36512367 SPIRIT-DEFINE: Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386. PMID: 37863491 SPIRIT Factorial: Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, Little P, Fletcher J, Golub RM, Goulao B, Hopewell S, Islam N, Zwarenstein M, Chan AW, Montgomery AA. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open. 2023;6(12):e2346121. PMID: 38051535 SPIRIT-Surrogate: Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525. PMID: 38981624 SPIRIT-iNeurostim: Bresnahan R, Copley S, Eldabe S, Thomson S, North RB, Baranidharan G, Levy RM, Collins GS, Taylor RS, Duarte RV. Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension. EClinicalMedicine. 2024;78:102933. PMID: 39610902 |
| Reporting guideline acronym | SPIRIT-C |
| Study design | Clinical trials |
| Applies to the whole report or to individual sections of the report? | Whole report |
| Record last updated on | April 16, 2026 |